EmblemHealth, a US-based non-profit health insurer, has cut the number of medical procedures for which members will require prior authorisation before receiving care, effective 1 January 2020, it was reported yesterday.
The change affects all of the company's health insurance plans, including Medicaid managed care, Medicare Advantage, coverage provided through employers, and Individual Market plans on the Exchange.
Karen Ignagni, president and CEO of EmblemHealth, said, 'EmblemHealth is transforming all of its operations. As part of that effort, we are reducing red tape and simplifying administrative processes for our clinical partners. This has led us to cut prior authorisation requirements in half. Through careful analysis of our data, we identified services that almost always get approved. Not requiring prior authorisation of those services, such as surgical procedures where patients are going to the hospital (ie some cardiac and vascular procedures, gallbladder removal and treatment of glaucoma), will ensure that our members are receiving the care they need quickly and efficiently. Looking forward, we will continue to review our data with the goal of finding additional ways to reduce red tape and simplify administrative procedures.'
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions
Corstasis and U.S. Heart and Vascular partner to advance heart failure care with ENBUMYST
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Merck reports positive Phase 3 results for oral PCSK9 inhibitor enlicitide
Abbott's Navitor TAVI system granted CE Mark for expanded indication
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
FDA lifts clinical hold on Rocket Pharmaceuticals' RP-A501 Phase 2 Danon disease trial
OptiBiotix signs distribution deal with major weight management company
Novartis to present cardiovascular abstracts portfolio data at ESC Congress in Madrid
LivaNova announces commercial launch of Essenz Perfusion System in China
Viatris' generic iron sucrose injection gains US FDA approval
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio